StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
BEAT$0.88+1.03%
Fair $0.88+0.0%

BEAT

HeartBeam, Inc.

Healthcare / Health Information ServicesNasdaqCM

$0.88

+0.01 (+1.03%)

Fairly Valued+0.0%Fair Value $0.88Fund rank 27/100 · Data gapFallback financials|
SA 4/F
F-Score: 2/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 23%

FCF escenarios

weak_data · normalized FCF $-14.6M · quality 52.0/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 41/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

4/100

F

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 6Warnings: 1unknown: 6
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -8.1%, below the 5% threshold
Thesis & Journal · BEATLocal privado en este navegador · HeartBeam, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$49M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-807.3%

↓

Gross Margin

N/A

•

Debt/Equity

N/A

•
52-Week Range$1
$1$4

TradingView lightweight chart

BEAT price, volumen y niveles de valoración

Último $0.884Periodo -81.2%
Fair value: $0.884

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2020–2025 · 5 años de histórico normalizado

Revenue CAGR

—

FCF CAGR

—

FCF margin

—

FCF / Net income

0.69x

Latest source

Provider fallback

Margin decomposition

Último año: revenue — · net income $-21.0M · FCF $-14.6M

2020-FY → 2025-FY

Gross margin

—— pts

Operating margin

—— pts

Net margin

—— pts

FCF margin

—— pts
MetricTTM
2025
2024
2023
2022
2021
2020
Income Statement
Net Income$-21.0M$-21.0M$-19.4M$-14.6M$-13.0M$-4.4M$-1.1M
EBITDA$-21.1M$-21.1M$-19.9M$-15.3M$-13.0M——
EPS——-0.73-0.72-1.59-1.03-0.29
Balance Sheet
Current Ratio0.740.74—————
Cash Flow
Free Cash Flow$-14.6M$-14.6M$-14.7M$-12.3M$-9.9M——
Returns
ROE-807.3%-807.3%-1175.8%-91.9%-546.0%-33.0%22.3%
Valuation
P/B13.6213.6236.092.8314.55——
Growth & Yield
EPS Growth——-1.4%54.7%—-255.2%—

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -48.0%

Total return

-48.0%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.73 → n/d

Residual

-48.0%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-48.0%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.